Effect of retinal photocoagulation combined with Conbercept on the levels of vascular endothelial growth factor and SDF-1 in aqueous humor of DR patients

• Main Authors: Rong Chen, Hui-Qing Sun, Lan Chen
• Format: Article
• Language: English
• Published: Press of International Journal of Ophthalmology (IJO PRESS) 2019-07-01
• Series: Guoji Yanke Zazhi
• Subjects: retinal photocoagulation; conbercept; diabetic retinopathy; vascular endothelial growth factor; stromal cell-derived factor-1
• Online Access: http://ies.ijo.cn/cn_publish/2019/7/201907022.pdf
• ISSN: 1672-5123; 1672-5123

AIM:To discuss the effect of retinal photocoagulation combined with conbercept on the aqueous humor vascular endothelial growth factor(VEGF)and stromal cell-derived factor-1(SDF-1)in patients with diabetic retinopathy(DR). <p>METHODS: Totally 120 patients with DR were selected from September 2016 to September 2018 in our hospital, according to the random number table, they were divided into combined group and photocoagulation group, 60 cases in each group. The photocoagulation group was treated with retinal photocoagulation, and the combined group was treated with retinal photocoagulation combined intravitreal injection of conbercept. The aqueous humor VEGF, SDF-1, CMT, BCVA and complication were compared between the two groups. <p>RESULTS: The postoperative aqueous humor(151.46±18.52,186.74±20.17pg/mL), SDF-1(466.72±50.21, 534.46±56.24mg/L)in the combined group and photocoagulation group were significantly lower than those in the preoperative, the combined group were lower than the photocoagulation group(<i>P</i><0.05). The 1 and 3mo postoperative CMT, BCVA in the combined group and photocoagulation group were significantly lower than those in the preoperative, the combined group were lower than the photocoagulation group(<i>P</i><0.05). There was no significant difference of the complication rate between combined group and photocoagulation group(6.7% <i>vs</i> 5.0%, <i>P</i>>0.05). <p>CONCLUSION: Retinal photocoagulation combined with conbercept can effectively reduce the aqueous humor VEGF and SDF-1 in patients with DR, which is conducive to improving the therapeutic effect of patients, and it is safety.